KalVista Pharmaceuticals had its Relative Strength (RS) Rating upgraded from 90 to 93 Thursday.
How To Use Stock Charts To Stay Profitable And Protected
IBD's unique RS Rating measures technical performance by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks matches up against all other stocks in our database.
Over 100 years of market history shows that the stocks that go on to make the biggest gains often have an 80 or higher RS Rating as they begin their biggest runs.
KalVista Pharmaceuticals is now considered extended and out of buy range after clearing an 11.45 buy point in a first-stage cup without handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
KalVista Pharmaceuticals reported 0% earnings growth in the latest quarterly report. Revenue rose 0%. The next quarterly numbers are expected on or around Jul. 10.
The company holds the No. 157 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
